PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer

2014-12-10
(Press-News.org) JACKSONVILLE, Fla. -- A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker -- the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy -- appears irrelevant when trastuzumab is used.

And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in order to predict outcome, say researchers from Mayo Clinic in Florida.

These findings, presented at the 2014 San Antonio Breast Cancer Symposium, don't mean that immune function in this class of cancer isn't important -- just that it is likely more complicated than measuring the number of these lymphocytes, says the study's lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.

"Researchers are really interested in the different components of the immune system as a predictor of the natural history of breast cancer and benefit from different therapies, but it may be that when trastuzumab is used, it is the function of the immune system and not the number of lymphocytes that is important," Dr. Perez says.

She also pointed out that S-TILs can do two things -- they can promote the killing of tumors but they can also actually create substances to help cancer grow. "We don't know what effect they have when trastuzumab is used," she says.

The study measured S-TILs at diagnosis in about 1,000 patients with early stage HER2-positive breast cancer enrolled in the N9831 study, which tested chemotherapy alone or chemotherapy with trastuzumab. Only patients treated with chemotherapy alone showed improved recurrence-free survival when the S-TILs score was high.

The findings contradict a smaller study of HER2-positive patients that found increased levels of S-TILs were linked to increased trastuzumab benefit. That study suggested that tumors of patients with HER2-positive disease should be tested for their S-TILs score in order to determine therapy benefit.

"Ours is a much more definitive study, showing this testing is not necessary in this subset of patients with HER2-positive breast cancer," Dr. Perez says.

"This study is part of a series we are conducting to determine which patients should use trastuzumab. We are now giving it to everyone whose tumors are HER2-positive, but not every patient benefits," she says.

INFORMATION:

Researchers from Mayo Clinic in Rochester, Indiana University, Genomic Health and the University of California San Francisco participated in the study.

The study was partially funded by Mayo Clinic, the 26.2 with Donna Foundation and the Breast Cancer Research Foundation, and by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology and CA025224 to the legacy North Central Cancer Treatment Group (NCCTG). This study is registered on http://www.clinicaltrials.gov as NCT00005970.

About Mayo Clinic Cancer Center As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.


About Mayo Clinic Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, MayoClinic.org or newsnetwork.mayoclinic.org.

About the Alliance for Clinical Trials in Oncology The Alliance for Clinical Trials in Oncology is a national clinical trials network sponsored by the National Cancer Institute that consists of a network of nearly 10,000 cancer specialists at hospitals, medical centers, and community sites across the country and Canada. The Alliance is dedicated to developing and conducting clinical trials with promising new cancer therapies, and utilizes the best science to develop optimal treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments. To learn more about the Alliance, visit allianceforclinicaltrialsinoncology.org. MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs (on-site during San Antonio Breast Cancer Symposium), 651-261-9089 (cell). Email: dangor.yusuf@mayo.edu.

Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199. Email: scotti.paul@mayo.edu. MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.



ELSE PRESS RELEASES FROM THIS DATE:

Early trial of new drug shows promise for patients with triple-negative breast cancer

Early trial of new drug shows promise for patients with triple-negative breast cancer
2014-12-10
In patients with metastatic triple-negative breast cancer--a disease with no approved targeted therapies--infusion of pembrolizumab produced durable responses in almost one out of five patients enrolled in a phase-Ib clinical trial, according to data presented Dec. 10, at the 2014 San Antonio Breast Cancer Symposium. The multi-center, non-randomized trial was designed to evaluate the safety, tolerability and antitumor activity of bi-weekly infusions of pembrolizumab (MK-3475, marketed as Keytruda®). The researchers enrolled 27 patients, aged 29 to 72 years, who had ...

Link between power lines and ill-health called into question

2014-12-10
Several past studies have suggested that the magnetic fields created by phones, high-voltage power lines and other electrical equipment are harmful for humans. Research first carried out in the 1970's and again subsequently, found an association between people living near overhead power lines and an increased risk of childhood leukaemia. Although some later studies have failed to find such a link, the International Agency for Research on Cancer has categorised low frequency magnetic fields as "possibly carcinogenic." But a mechanism for this association has never been ...

Brain inflammation a hallmark of autism, large-scale analysis shows

2014-12-10
While many different combinations of genetic traits can cause autism, brains affected by autism share a pattern of ramped-up immune responses, an analysis of data from autopsied human brains reveals. The study, a collaborative effort between Johns Hopkins and the University of Alabama at Birmingham, included data from 72 autism and control brains. It will be published online Dec. 10 in the journal Nature Communications. "There are many different ways of getting autism, but we found that they all have the same downstream effect," says Dan Arking, Ph.D. , an associate professor ...

Defects are perfect in laser-induced graphene

Defects are perfect in laser-induced graphene
2014-12-10
HOUSTON - (Dec. 10, 2014) - Researchers at Rice University have created flexible, patterned sheets of multilayer graphene from a cheap polymer by burning it with a computer-controlled laser. The process works in air at room temperature and eliminates the need for hot furnaces and controlled environments, and it makes graphene that may be suitable for electronics or energy storage. Under a microscope, what the researchers call laser-induced graphene (LIG) doesn't look like a perfect chicken wire-like grid of atoms. Instead, it's a jumble of interconnected graphene flakes ...

Brain reward circuits respond differently to 2 kinds of sugar

2014-12-10
Phoenix, AZ (December 10th, 2014) - The brain responds differently to two kinds of sugar, according to a report today at the American College of Neuropsychopharmacology annual meeting in Phoenix Arizona. The study suggests that fructose heightens the response of brain reward circuits to food cues, promoting feeding behavior. Currently, roughly two out of three U.S. adults are overweight and one out of three is obese. Changes in lifestyle and dietary intake during the past quarter century are thought to be the main culprits, with the increase in fructose consumption of ...

Alcohol-control law may curb partner abuse

2014-12-10
PISCATAWAY, NJ - Communities with fewer places to buy or drink alcohol also tend to have lower rates of intimate partner violence, new evidence suggests. The research, published in the January issue of the Journal of Studies on Alcohol and Drugs, suggests that laws limiting what is called "alcohol outlet density" could offer one way to address violence within intimate relationships. States and communities throughout the United States have enacted various laws to reduce excessive use of alcohol, including limiting outlet density, limiting hours and days of sale, and ...

Saving old information can boost memory for new information

2014-12-10
The simple act of saving something, such as a file on a computer, may improve our memory for the information we encounter next, according to new research published in Psychological Science, a journal of the Association for Psychological Science. The research suggests that the act of saving helps to free up cognitive resources that can be used to remember new information. Our findings show that people are significantly better at learning and remembering new information when they save previous information," says psychological scientist and study author Benjamin Storm of ...

Drug developed at Pitt proves effective against antibiotic-resistant 'superbugs'

Drug developed at Pitt proves effective against antibiotic-resistant superbugs
2014-12-10
PITTSBURGH, Dec. 9, 2014 - A treatment pioneered at the University of Pittsburgh Center for Vaccine Research (CVR) is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes. The findings, announced online in the journal Antimicrobial Agents and Chemotherapy and funded by the National Institutes of Health, provide a needed boost to the field of antibiotic development, which has been limited in the last four ...

Can organic crops compete with industrial agriculture?

Can organic crops compete with industrial agriculture?
2014-12-10
Berkeley -- A systematic overview of more than 100 studies comparing organic and conventional farming finds that the crop yields of organic agriculture are higher than previously thought. The study, conducted by researchers at the University of California, Berkeley, also found that certain practices could further shrink the productivity gap between organic crops and conventional farming. The study, to be published online Wednesday, Dec. 10, in the Proceedings of the Royal Society B, tackles the lingering perception that organic farming, while offering an environmentally ...

Experts call for faster mobilization of 'overlooked' survivors to contain Ebola epidemic

2014-12-10
In an editorial published online today in the International Journal of Epidemiology, experts from the Departments of Psychiatry and Epidemiology at Columbia University, New York, are calling for survivors of the Ebola epidemic to be mobilised in a bid to hasten containment of the disease. We already know that the current Ebola outbreak is unique in its magnitude and for its dispersion in dense, mobile populations. Physicians and nurses face high mortality, and foreign aid in the form of medical supplies and staff continues to be unequal to the scope of the problem. With ...

LAST 30 PRESS RELEASES:

New perspective highlights urgent need for US physician strike regulations

An eye-opening year of extreme weather and climate

Scientists engineer substrates hostile to bacteria but friendly to cells

New tablet shows promise for the control and elimination of intestinal worms

Project to redesign clinical trials for neurologic conditions for underserved populations funded with $2.9M grant to UTHealth Houston

Depression – discovering faster which treatment will work best for which individual

Breakthrough study reveals unexpected cause of winter ozone pollution

nTIDE January 2025 Jobs Report: Encouraging signs in disability employment: A slow but positive trajectory

Generative AI: Uncovering its environmental and social costs

Lower access to air conditioning may increase need for emergency care for wildfire smoke exposure

Dangerous bacterial biofilms have a natural enemy

Food study launched examining bone health of women 60 years and older

CDC awards $1.25M to engineers retooling mine production and safety

Using AI to uncover hospital patients’ long COVID care needs

$1.9M NIH grant will allow researchers to explore how copper kills bacteria

New fossil discovery sheds light on the early evolution of animal nervous systems

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

Study shows how plant roots access deeper soils in search of water

Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs

‘What is that?’ UCalgary scientists explain white patch that appears near northern lights

How many children use Tik Tok against the rules? Most, study finds

Scientists find out why aphasia patients lose the ability to talk about the past and future

Tickling the nerves: Why crime content is popular

Intelligent fight: AI enhances cervical cancer detection

Breakthrough study reveals the secrets behind cordierite’s anomalous thermal expansion

Patient-reported influence of sociopolitical issues on post-Dobbs vasectomy decisions

Radon exposure and gestational diabetes

EMBARGOED UNTIL 1600 GMT, FRIDAY 10 JANUARY 2025: Northumbria space physicist honoured by Royal Astronomical Society

Medicare rules may reduce prescription steering

Red light linked to lowered risk of blood clots

[Press-News.org] Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer